Compare OMCL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMCL | OGN |
|---|---|---|
| Founded | 1992 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2000 | 2020 |
| Metric | OMCL | OGN |
|---|---|---|
| Price | $32.08 | $13.75 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $55.83 | $11.40 |
| AVG Volume (30 Days) | 524.3K | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.77 | ★ 0.95 |
| Revenue | $787,309,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $6.77 | $0.45 |
| Revenue Next Year | $5.22 | $1.67 |
| P/E Ratio | $41.99 | ★ $14.41 |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $29.06 | $5.69 |
| 52 Week High | $51.84 | $13.79 |
| Indicator | OMCL | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 59.13 |
| Support Level | $32.15 | $13.46 |
| Resistance Level | $35.61 | $13.79 |
| Average True Range (ATR) | 0.97 | 0.04 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 6.31 | 64.52 |
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.